ClinicaSpace.com
Clinical Research
News & Careers
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login   

By Industry | By Industry Segment | By Services and Suppliers | By Location | Profile Search
 Company Profile

 

Daiichi Sankyo, Inc. 

U.S. Corporate Headquarters
Two Hilton Court
Parsippany  New Jersey  07054  U.S.A.
Phone: 973-944-2600 Fax: 973-359-2645


SEARCH JOBS

About Daiichi Sankyo, Inc.

Daiichi Sankyo Inc., headquartered in Parsippany, New Jersey, is the U.S. subsidiary of Tokyo-based Daiichi Sankyo Co., Ltd., which is a global pharmaceutical innovator.

The headquarters company was established in 2005 from the merger of two leading Japanese pharmaceutical companies. This integration created a more robust organization that allows for continuous development of novel drugs that enrich the quality of life for patients around the world.

A central focus of Daiichi Sankyo's research and development is cardiovascular disease, including therapies for dyslipidemia, hypertension, diabetes and acute coronary syndrome. Also important to the company is the discovery of new medicines in the areas of infectious diseases, cancer, bone and joint diseases, and immune disorders.


This div will be replaced



 Key Statistics


Email:
Ownership: Public

Web Site: Daiichi Sankyo, Inc.
Employees: 3,000 in the U.S.
Symbol: 4568.t
 



Industry
Pharmaceutical






 Company News
Perosphere Inc. And Daiichi Sankyo, Inc. (4568.t) Enter Into A Clinical Trial Collaboration Agreement For Phase 3 Studies Of PER977 To Investigate Reversal Of The Anticoagulant Activity Of The Investigational Factor Xa-Inhibitor Edoxaban 10/6/2014 10:28:29 AM
Daiichi Sankyo, Inc. (4568.t) Boosts Cancer Pipeline With $410 Million Ambit Biosciences Buy 9/29/2014 5:58:51 AM
Daiichi Sankyo, Inc. (4568.t) Receives Approval For Additional Indications Of LIXIANA® (Edoxaban) In Japan 9/26/2014 8:30:52 AM
Daiichi Sankyo, Inc. (4568.t) Release: One Year Data From The PREFER In AF Registry Show Significant Changes In Atrial Fibrillation (AF) Management In Europe And Implementation Of Clinical Guidelines 9/2/2014 1:26:06 PM
Daiichi Sankyo, Inc. (4568.t) Wagers Up To $650 Million On Charleston Laboratories, Inc.'s Pain And Opioid-Induced Nausea And Vomiting Drug 8/7/2014 8:43:55 AM
Daiichi Sankyo, Inc. (4568.t) And Eli Lilly and Company (LLY): Heart Patients In England And Wales Offered More Choice Of Therapies As National Institute for Clinical Excellence (NICE) Extends Recommendations For Prasugrel 7/23/2014 11:01:12 AM
Portola Pharmaceuticals, Inc. Enters Into Clinical Collaboration Agreement With Daiichi Sankyo, Inc. (4568.t) For Phase 3 Studies Of Factor Xa Inhibitor Antidote, Andexanet Alfa, And Edoxaban 7/7/2014 12:35:34 PM
Pieris Achieves Milestone Payment In Daiichi Sankyo, Inc. (4568.t) Collaboration To Develop Anticalin® Therapeutics 6/23/2014 8:51:22 AM
Sanford-Burnham Medical Research Institute And Daiichi Sankyo, Inc. (4568.t) Form AllianceTo Study Novel Drug Targets In Cardiovascular-Metabolic Diseases 5/21/2014 12:58:14 PM
MRC Technology And Daiichi Sankyo, Inc. (4568.t) Collaborate To Identify Novel Targets For Drug Discovery 5/14/2014 10:21:29 AM
12345678910...